Adaptimmune Therapeutics (STU:473A) Capital Expenditure : €-3.33 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Adaptimmune Therapeutics's cash flow for capital expenditures for the three months ended in Mar. 2025 was €-1.1 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was €-3.33 Mil.

Adaptimmune Therapeutics Capital Expenditure Historical Data

The historical data trend for Adaptimmune Therapeutics's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Capital Expenditure Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Capital Expenditure

Get a 7-Day Free Trial

-2.39

-7.77

-28.08

-4.48

-2.60

Adaptimmune Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Capital Expenditure	Get a 7-Day Free Trial															-0.33	-0.70	-0.39	-1.12	-1.11

Adaptimmune Therapeutics Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.33 Mil.

Adaptimmune Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

ADAP:USA 473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines